Siyu Xia, Wenting Ye, Jiajun Zeng, Ge Song, Yan Sun, Yongmei Zhang, Xiaoqing Luo, Jing Cai, Hongjin Yu, Wenwei Pan, Jiayun Chen, Chuanbin Yang, Qingming Luo, Jigang Wang, Yali Song
Intrauterine adhesion (IUA) is a common endometrial disease caused by injury, leading to reproductive health issues. Current treatments have limited effectiveness, side effects, and high recurrence rates, especially, in severe cases. However, the underlying molecular and cellular mechanisms are largely unknown. Here we performed a comprehensive analysis by profiling integrated single-cell transcriptomes of over 72,000 individual endometrial cells, encompassing samples from both patients with IUA and those with normal endometrium. We identified changes in cell type-specific molecular signatures, including the inflammatory activation in immune cells, extensive damage in epithelial subpopulations, and the deposition of collagen secreted by fibroblasts subpopulations. Our results demonstrated activation of the TREM2+ macrophages, which displayed properties of inflammatory regulation. Annexin A1+ NK subpopulations exhibited the highest susceptibility among NK subtypes, displaying decreased cellular density and the most pronounced differential gene expression. Furthermore, we identified the matrix metallopeptidase 7 (MMP7+) and C-C motif chemokine ligand 5 (CCL5+) unciliated epithelial subtype originated from pituitary tumor-transforming gene 1 (PTTG1+) unciliated epithelium as the most vulnerable subpopulations to epithelial injury. Collectively, our study offers integrated resources of the cellular microenvironment of IUA, serving as a comprehensive cellular map of the disease in affected individuals. The insights gained from this study are expected to provide valuable resources for future diagnostic and therapeutic approaches.
宫腔内粘连(IUA)是一种常见的子宫内膜疾病,由损伤引起,导致生殖健康问题。目前的治疗方法效果有限,副作用大,复发率高,尤其是在严重的情况下。然而,潜在的分子和细胞机制在很大程度上还不为人所知。在此,我们对超过 72,000 个子宫内膜细胞的单细胞转录组进行了综合分析,其中包括 IUA 患者和正常子宫内膜患者的样本。我们发现了细胞类型特异性分子特征的变化,包括免疫细胞的炎症激活、上皮亚群的广泛损伤以及成纤维细胞亚群分泌的胶原蛋白沉积。我们的研究结果表明,TREM2+巨噬细胞被激活,显示出炎症调节的特性。在 NK 亚型中,Annexin A1+ NK 亚群表现出最高的易感性,细胞密度降低,基因表达差异最明显。此外,我们还发现基质金属肽酶 7(MMP7+)和 C-C motif 趋化因子配体 5(CCL5+)无纤毛上皮亚型是最易受上皮损伤影响的亚群,它们源自垂体肿瘤转化基因 1(PTTG1+)无纤毛上皮。总之,我们的研究提供了 IUA 细胞微环境的综合资源,可作为受影响个体疾病的全面细胞图谱。从这项研究中获得的见解有望为未来的诊断和治疗方法提供宝贵的资源。
{"title":"A single-cell transcriptomic atlas of severe intrauterine adhesion","authors":"Siyu Xia, Wenting Ye, Jiajun Zeng, Ge Song, Yan Sun, Yongmei Zhang, Xiaoqing Luo, Jing Cai, Hongjin Yu, Wenwei Pan, Jiayun Chen, Chuanbin Yang, Qingming Luo, Jigang Wang, Yali Song","doi":"10.1002/mef2.70003","DOIUrl":"https://doi.org/10.1002/mef2.70003","url":null,"abstract":"<p>Intrauterine adhesion (IUA) is a common endometrial disease caused by injury, leading to reproductive health issues. Current treatments have limited effectiveness, side effects, and high recurrence rates, especially, in severe cases. However, the underlying molecular and cellular mechanisms are largely unknown. Here we performed a comprehensive analysis by profiling integrated single-cell transcriptomes of over 72,000 individual endometrial cells, encompassing samples from both patients with IUA and those with normal endometrium. We identified changes in cell type-specific molecular signatures, including the inflammatory activation in immune cells, extensive damage in epithelial subpopulations, and the deposition of collagen secreted by fibroblasts subpopulations. Our results demonstrated activation of the TREM2<sup>+</sup> macrophages, which displayed properties of inflammatory regulation. Annexin A1<sup>+</sup> NK subpopulations exhibited the highest susceptibility among NK subtypes, displaying decreased cellular density and the most pronounced differential gene expression. Furthermore, we identified the matrix metallopeptidase 7 (MMP7<sup>+</sup>) and C-C motif chemokine ligand 5 (CCL5<sup>+</sup>) unciliated epithelial subtype originated from pituitary tumor-transforming gene 1 (PTTG1<sup>+</sup>) unciliated epithelium as the most vulnerable subpopulations to epithelial injury. Collectively, our study offers integrated resources of the cellular microenvironment of IUA, serving as a comprehensive cellular map of the disease in affected individuals. The insights gained from this study are expected to provide valuable resources for future diagnostic and therapeutic approaches.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laurence Si Chong Lok, Shuvam Sarkar, Calista Chi In Lam, Chak Fun Law, Sin Teng Chau, Chun Yip Thomas Leung, Wai Hin Cheang, Ting Li, Olivia Monteiro, Daniel Tomas Baptista-Hon
Long coronavirus disease (COVID) is characterized by persistent symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and has emerged as a significant health concern. As SARS-CoV-2 evolved from the wild-type strain to the Alpha, Beta, Delta, and Omicron variants, there may be a variant-specific influence on long COVID akin to the acute disease. This review aims to summarize our current knowledge of variant-specific influences in long COVID incidence, symptom profile as well as mechanisms of pathogenesis. We highlight that long COVID incidence may be lower with the Omicron variants. The symptom profile of long COVID may also show some dependence on the different variants, with a reduction in cardiopulmonary symptoms with more recent SARS-CoV-2 variants. This heterogeneity of long COVID may also be related to the variant-specific differences in affecting the immune system, viral persistence, and autoimmunity. However, emerging data also suggest that vaccinations may play a big role in shaping the presentation of long COVID. We also highlight ongoing work on long COVID incidence and symptom profiles in populations infected only by the Omicron variants. This will be beneficial toward more useful disease definitions and the development of effective diagnostic and therapeutic strategies.
{"title":"Long COVID across SARS-CoV-2 variants: Clinical features, pathogenesis, and future directions","authors":"Laurence Si Chong Lok, Shuvam Sarkar, Calista Chi In Lam, Chak Fun Law, Sin Teng Chau, Chun Yip Thomas Leung, Wai Hin Cheang, Ting Li, Olivia Monteiro, Daniel Tomas Baptista-Hon","doi":"10.1002/mef2.70004","DOIUrl":"https://doi.org/10.1002/mef2.70004","url":null,"abstract":"<p>Long coronavirus disease (COVID) is characterized by persistent symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and has emerged as a significant health concern. As SARS-CoV-2 evolved from the wild-type strain to the Alpha, Beta, Delta, and Omicron variants, there may be a variant-specific influence on long COVID akin to the acute disease. This review aims to summarize our current knowledge of variant-specific influences in long COVID incidence, symptom profile as well as mechanisms of pathogenesis. We highlight that long COVID incidence may be lower with the Omicron variants. The symptom profile of long COVID may also show some dependence on the different variants, with a reduction in cardiopulmonary symptoms with more recent SARS-CoV-2 variants. This heterogeneity of long COVID may also be related to the variant-specific differences in affecting the immune system, viral persistence, and autoimmunity. However, emerging data also suggest that vaccinations may play a big role in shaping the presentation of long COVID. We also highlight ongoing work on long COVID incidence and symptom profiles in populations infected only by the Omicron variants. This will be beneficial toward more useful disease definitions and the development of effective diagnostic and therapeutic strategies.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.70004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142860012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Next-generation sequencing (NGS) has emerged as a transformative technology in oncology, revolutionizing cancer diagnostics and personalized treatment strategies. By providing comprehensive insights into the genetic landscape of tumors, NGS enables the identification of critical somatic and germline mutations, copy number variations (CNVs), and gene fusions. Over the past decade, advancements in NGS platforms have led to greater accuracy, speed, and cost-effectiveness, making it an integral part of cancer research and clinical diagnostics. Despite its widespread adoption, significant challenges remain, including the need for improved methods to detect minimal residual disease (MRD) and accurately profile tumor heterogeneity. This review explores the evolution of NGS technologies and their pivotal role in cancer biology, from early diagnostics to therapeutic guidance. It delves into the application of NGS in identifying CNVs and gene fusions, monitoring MRD, and the increasing relevance of targeted NGS and spatial genomics. Furthermore, the integration of spatial transcriptomics is highlighted as a frontier in understanding the tumor microenvironment. By addressing these critical aspects, this review provides a comprehensive overview of how NGS is shaping the future of cancer research and treatment, offering a complete overview of potential NGS applications in scientific and clinical oncology.
{"title":"Role of next-generation sequencing in revolutionizing healthcare for cancer management","authors":"Om Saswat Sahoo, Hiya Aidasani, Arnab Nayek, Smita Tripathi, Joyeeta Talukdar, Anamta Gul, Deepak Kumar, Ruby Dhar, Subhradip Karmakar","doi":"10.1002/mef2.70001","DOIUrl":"https://doi.org/10.1002/mef2.70001","url":null,"abstract":"<p>Next-generation sequencing (NGS) has emerged as a transformative technology in oncology, revolutionizing cancer diagnostics and personalized treatment strategies. By providing comprehensive insights into the genetic landscape of tumors, NGS enables the identification of critical somatic and germline mutations, copy number variations (CNVs), and gene fusions. Over the past decade, advancements in NGS platforms have led to greater accuracy, speed, and cost-effectiveness, making it an integral part of cancer research and clinical diagnostics. Despite its widespread adoption, significant challenges remain, including the need for improved methods to detect minimal residual disease (MRD) and accurately profile tumor heterogeneity. This review explores the evolution of NGS technologies and their pivotal role in cancer biology, from early diagnostics to therapeutic guidance. It delves into the application of NGS in identifying CNVs and gene fusions, monitoring MRD, and the increasing relevance of targeted NGS and spatial genomics. Furthermore, the integration of spatial transcriptomics is highlighted as a frontier in understanding the tumor microenvironment. By addressing these critical aspects, this review provides a comprehensive overview of how NGS is shaping the future of cancer research and treatment, offering a complete overview of potential NGS applications in scientific and clinical oncology.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.70001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hong-Xia Li, Ying-Ying Han, Hong-Xiang Yu, Lu-Feng Wang, Can Cui, Ling-Ting Jin, Meng-Ru Ge, Xue Gao, Gang Li, Yong-Bo Hu, Bei Zhang
Acute ischemic stroke (AIS) is characterized by high morbidity and mortality, making it crucial to identify the risk factors that influence its occurrence and prognosis. Although individuals with thyroid dysfunction exhibit altered stroke patterns, evidence from observational studies remains inconsistent. Herein, we investigated the influence of thyroid dysfunction on stroke progression and prognosis. We combined Mendelian randomization (MR) and tandem mass tag (TMT)-based quantitative proteomics analysis to study the influence of thyroid dysfunction on AIS. Differentially expression proteins (DEPs) were subsequently identified, functional enrichment analysis was performed, and a protein–protein interaction (PPI) network was constructed. Protein alterations were further validated by western blot. MR analysis revealed a causal association between thyroid disorders and ischemic stroke. DEP analysis identified 38 downregulated proteins and five upregulated proteins. Functional enrichment analysis and PPI network construction highlighted the importance of immune response activation and acute phase pathways, along with the suppression of focal adhesion, regulation of the actin cytoskeleton, and platelet activation pathways. Vasodilator-stimulated phosphoprotein, MYL12B, MYL6, and TPM4 were identified as key DEPs significantly associated with pathological pathways and were verified by western blot. The identification of these key proteins and pathways provides new perspectives for investigating the progression and prognosis of AIS.
急性缺血性卒中(AIS)的特点是发病率和死亡率高,因此确定影响其发生和预后的风险因素至关重要。尽管甲状腺功能障碍患者的卒中模式有所改变,但观察性研究的证据仍不一致。在此,我们研究了甲状腺功能障碍对中风进展和预后的影响。我们结合孟德尔随机化(MR)和基于串联质量标签(TMT)的定量蛋白质组学分析,研究甲状腺功能障碍对 AIS 的影响。随后鉴定了差异表达蛋白(DEPs),进行了功能富集分析,并构建了蛋白-蛋白相互作用(PPI)网络。蛋白质的改变通过 Western 印迹得到进一步验证。磁共振分析显示甲状腺疾病与缺血性中风之间存在因果关系。DEP分析确定了38个下调蛋白和5个上调蛋白。功能富集分析和 PPI 网络构建强调了免疫反应激活和急性期通路的重要性,以及抑制病灶粘附、调节肌动蛋白细胞骨架和血小板活化通路的重要性。血管舒张剂刺激磷蛋白、MYL12B、MYL6 和 TPM4 被确定为与病理通路显著相关的关键 DEPs,并通过 Western 印迹进行了验证。这些关键蛋白和通路的鉴定为研究 AIS 的进展和预后提供了新的视角。
{"title":"Combined Mendelian randomization and quantitative proteomics analysis to study the influence of thyroid dysfunction on acute ischemic stroke","authors":"Hong-Xia Li, Ying-Ying Han, Hong-Xiang Yu, Lu-Feng Wang, Can Cui, Ling-Ting Jin, Meng-Ru Ge, Xue Gao, Gang Li, Yong-Bo Hu, Bei Zhang","doi":"10.1002/mef2.70002","DOIUrl":"https://doi.org/10.1002/mef2.70002","url":null,"abstract":"<p>Acute ischemic stroke (AIS) is characterized by high morbidity and mortality, making it crucial to identify the risk factors that influence its occurrence and prognosis. Although individuals with thyroid dysfunction exhibit altered stroke patterns, evidence from observational studies remains inconsistent. Herein, we investigated the influence of thyroid dysfunction on stroke progression and prognosis. We combined Mendelian randomization (MR) and tandem mass tag (TMT)-based quantitative proteomics analysis to study the influence of thyroid dysfunction on AIS. Differentially expression proteins (DEPs) were subsequently identified, functional enrichment analysis was performed, and a protein–protein interaction (PPI) network was constructed. Protein alterations were further validated by western blot. MR analysis revealed a causal association between thyroid disorders and ischemic stroke. DEP analysis identified 38 downregulated proteins and five upregulated proteins. Functional enrichment analysis and PPI network construction highlighted the importance of immune response activation and acute phase pathways, along with the suppression of focal adhesion, regulation of the actin cytoskeleton, and platelet activation pathways. Vasodilator-stimulated phosphoprotein, MYL12B, MYL6, and TPM4 were identified as key DEPs significantly associated with pathological pathways and were verified by western blot. The identification of these key proteins and pathways provides new perspectives for investigating the progression and prognosis of AIS.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Platelets play an irreplaceable role in hemostasis and wound healing. However, beyond these classical roles, as the smallest anucleate cells in the blood stream, they are crucial for immune response which have inflammatory functions through specialized receptors and different signaling pathways, influencing both innate and adaptive immune response. Furthermore, many research have proved that platelets significantly contribute to tumor metastasis and are associated with poor prognoses in cancer patients through its coagulability and supporting an immunosuppressive tumor microenvironment. When tumor cells detach from the primary tumor mass and enter the bloodstream, they rapidly initiate the direct activation and adhesion of platelets, forming a protective microenvironment. This environment shields circulating tumor cells (CTCs) from the mechanical shear forces of blood flow and immune surveillance. Here we delve into the interaction between platelets and immunomodulation and explore the multifaceted roles and underlying mechanisms by which platelets influence tumor cell metastasis and tumor growth. Furthermore, we also discussed the diagnostic role of platelets in cancer occurrence and progression, as well as the feasibility and prospects of targeting platelets for antitumor immunotherapy. This review provides a multidimensional perspective and reference for platelet-related cancer treatment strategies and diagnosis.
{"title":"Small but mighty: Platelets as multifunctional architects of tumor metastasis and immune regulation","authors":"Leyi Tang, Hubing Shi, Yong Luo","doi":"10.1002/mef2.70000","DOIUrl":"https://doi.org/10.1002/mef2.70000","url":null,"abstract":"<p>Platelets play an irreplaceable role in hemostasis and wound healing. However, beyond these classical roles, as the smallest anucleate cells in the blood stream, they are crucial for immune response which have inflammatory functions through specialized receptors and different signaling pathways, influencing both innate and adaptive immune response. Furthermore, many research have proved that platelets significantly contribute to tumor metastasis and are associated with poor prognoses in cancer patients through its coagulability and supporting an immunosuppressive tumor microenvironment. When tumor cells detach from the primary tumor mass and enter the bloodstream, they rapidly initiate the direct activation and adhesion of platelets, forming a protective microenvironment. This environment shields circulating tumor cells (CTCs) from the mechanical shear forces of blood flow and immune surveillance. Here we delve into the interaction between platelets and immunomodulation and explore the multifaceted roles and underlying mechanisms by which platelets influence tumor cell metastasis and tumor growth. Furthermore, we also discussed the diagnostic role of platelets in cancer occurrence and progression, as well as the feasibility and prospects of targeting platelets for antitumor immunotherapy. This review provides a multidimensional perspective and reference for platelet-related cancer treatment strategies and diagnosis.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.70000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142641907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>We highlight a recent study published in <i>Nature</i> which explored the role of interleukin-11 (IL-11), a pro-inflammatory cytokine, in aging.<span><sup>1</sup></span> The study demonstrates how inhibiting IL-11 signaling can positively impact both healthspan and lifespan in mice, suggesting a novel target for antiaging therapies with significant implications for enhancing human longevity and quality of life.</p><p>Aging is an inevitable process characterized by a gradual decline in physiological functions, increasing vulnerability to diseases as well as mortality. Therefore, understanding the molecular mechanisms that drive aging is crucial for developing interventions that can extend not only the lifespan of people, but also the healthspan defined as the period of life spent in good health. This study found that IL-11 expression in mice increases with age in various tissues, including the liver, visceral gonadal white adipose tissue and skeletal muscle. This suggests that changes in IL-11 may drive the decline in physical and metabolic health observed in older animals. To explore the influence of IL-11, the researchers used genetically engineered mice lacking IL-11 or its receptor. These models showed significant health benefits, including improved metabolic health, reduced inflammation and decreased cellular senescence compared to wild-type controls. The absence of IL-11 signaling also protected the mice from age-related muscle decline, metabolic dysfunction and other age-associated diseases. Importantly, the genetic deletion of IL-11 extended the average lifespan by 24.9% (median lifespan increasing from 121 to 151 weeks) in both male and female mice.</p><p>In IL-11-deficient mice, some of the changes such as increased muscle strength were observed even in young mice. Therefore, the researchers administered an anti-IL-11 antibody to aged mice (75 weeks old) for 25 weeks. This resulted in significant improvements in metabolic function, such as enhanced glucose tolerance and insulin sensitivity. Additionally, the mice treated with the antibody exhibited better muscle strength and lower levels of aging biomarkers, including pro-inflammatory cytokines, telomere length and tissue fibrosis. Similar to IL-11 knockout, the administration of anti IL-11 antibodies extended the median lifespan by 22.5% in male mice and 25% in female mice. Intriguingly, both IL-11-knockout mice and anti-IL-11-treated mice showed fewer macroscopic tumors compared to wild type mice at autopsy, suggesting IL-11 inhibition may have beneficial effects on cancer, a common cause of morbidity and mortality in old age. The study also evaluated the mechanisms by which IL-11 influences aging. Inhibiting IL-11 signaling reduced the activity of the ERK–AMPK–mTORC1 pathway, leading to reduced cellular senescence and inflammation. Additionally, IL-11 increased the expression of senescence-associated secretory phenotype factors, which exacerbate aging-related conditions.</p><p>The
因此,亟需可靠的生物标志物来更准确地预测生物年龄。端粒长度、DNA 甲基化模式(表观遗传时钟)等生物标志物以及上述方法都可以作为生物年龄的良好指标。人工智能(AI)方法无疑将在阐明受 IL-11 信号影响的复杂网络方面发挥重要作用,从而更深入地了解 IL-11 在衰老中的作用(图 1)。延长生命而不确保生活质量,尤其是身心健康方面的质量,可能会导致人们长期处于虚弱而非健康的状态。潜在抗衰老疗法的可及性和公平性也涉及伦理方面的考虑。如果可以使用 IL-11 抑制剂等疗法,必须确保社会各阶层都能使用,而不仅仅是富裕阶层。这就提出了更广泛的问题,即医疗保健的公平性和全球在获得医疗进步方面的差距。尽管如此,这项研究还是提供了令人信服的证据,证明抑制 IL-11 信号传导是一种很有前景的延长健康和寿命的新方法。随着研究不断揭示衰老的复杂机制,针对IL-11和类似通路的研究可能成为开发促进健康衰老和长寿的干预措施的核心:方法学(相同);写作-原稿(相同);写作-审阅和编辑(相同)。O Monteiro:方法学(相同);写作-原稿(相同);写作-审阅和编辑(相同)。D T Baptista-Hon:构思(主要);方法(等同);指导(主要);撰写原稿(等同);撰写-审阅和编辑(等同)。所有作者均已阅读并批准最终稿件。作者 Daniel T. Baptista-Hon 是 MedComm-Future Medicine 的编辑人员。作者Daniel T. Baptista-Hon没有参与该杂志对本稿件的审阅或相关决定。其他作者声明无利益冲突。
{"title":"Unlocking longevity: How blocking IL-11 signaling could extend healthspan and lifespan","authors":"L. S. C. Lok, O. Monteiro, D. T. Baptista-Hon","doi":"10.1002/mef2.101","DOIUrl":"https://doi.org/10.1002/mef2.101","url":null,"abstract":"<p>We highlight a recent study published in <i>Nature</i> which explored the role of interleukin-11 (IL-11), a pro-inflammatory cytokine, in aging.<span><sup>1</sup></span> The study demonstrates how inhibiting IL-11 signaling can positively impact both healthspan and lifespan in mice, suggesting a novel target for antiaging therapies with significant implications for enhancing human longevity and quality of life.</p><p>Aging is an inevitable process characterized by a gradual decline in physiological functions, increasing vulnerability to diseases as well as mortality. Therefore, understanding the molecular mechanisms that drive aging is crucial for developing interventions that can extend not only the lifespan of people, but also the healthspan defined as the period of life spent in good health. This study found that IL-11 expression in mice increases with age in various tissues, including the liver, visceral gonadal white adipose tissue and skeletal muscle. This suggests that changes in IL-11 may drive the decline in physical and metabolic health observed in older animals. To explore the influence of IL-11, the researchers used genetically engineered mice lacking IL-11 or its receptor. These models showed significant health benefits, including improved metabolic health, reduced inflammation and decreased cellular senescence compared to wild-type controls. The absence of IL-11 signaling also protected the mice from age-related muscle decline, metabolic dysfunction and other age-associated diseases. Importantly, the genetic deletion of IL-11 extended the average lifespan by 24.9% (median lifespan increasing from 121 to 151 weeks) in both male and female mice.</p><p>In IL-11-deficient mice, some of the changes such as increased muscle strength were observed even in young mice. Therefore, the researchers administered an anti-IL-11 antibody to aged mice (75 weeks old) for 25 weeks. This resulted in significant improvements in metabolic function, such as enhanced glucose tolerance and insulin sensitivity. Additionally, the mice treated with the antibody exhibited better muscle strength and lower levels of aging biomarkers, including pro-inflammatory cytokines, telomere length and tissue fibrosis. Similar to IL-11 knockout, the administration of anti IL-11 antibodies extended the median lifespan by 22.5% in male mice and 25% in female mice. Intriguingly, both IL-11-knockout mice and anti-IL-11-treated mice showed fewer macroscopic tumors compared to wild type mice at autopsy, suggesting IL-11 inhibition may have beneficial effects on cancer, a common cause of morbidity and mortality in old age. The study also evaluated the mechanisms by which IL-11 influences aging. Inhibiting IL-11 signaling reduced the activity of the ERK–AMPK–mTORC1 pathway, leading to reduced cellular senescence and inflammation. Additionally, IL-11 increased the expression of senescence-associated secretory phenotype factors, which exacerbate aging-related conditions.</p><p>The ","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lanni Zhou, Lizhu Ouyang, Baoliang Guo, Xiyi Huang, Shaomin Yang, Jialing Pan, Liwen Wang, Ming Chen, Fan Xie, Yunjing Li, Yongxing Du, Xinjie Chen, Qiugen Hu, Fusheng Ouyang
The detection of lymph node (LN) involvement is fundamental for staging colorectal cancer (CRC) and aids in clinical decision-making. Traditionally, determining LN status predominantly relies heavily on histological examination of LN specimens, which can occasionally lead to overtreatment. This study aims to develop a clinical prediction model using machine learning algorithms to assess the risk of mesenteric LN metastasis preoperatively, based on computed tomography images and clinicopathological data from CRC patients. Our findings demonstrate that the predictive model based on XGBoost algorithms exhibited the optimal performance, with area under the curve values consistently stable across training (0.836, 95% confidence interval [CI]: 0.750–0.902) and validation (0.831, 95% CI: 0.688–0.927) cohorts. The model was further elucidated using SHapley Additive Explanation values, which ranked predictors in the XGBoost model by their importance, providing insights into the model's decision-making process. Additionally, the force plot visualizes the contribution of each variable to the prediction for individual samples. The as-obtained model may have the potential to aid in clinical treatment planning, optimize the selection of surgical methods, and guide the decision-making process for adjuvant therapy before surgery.
{"title":"Enhanced prediction of preoperative mesenteric lymph node metastasis in colorectal cancer using machine learning with CT-based data","authors":"Lanni Zhou, Lizhu Ouyang, Baoliang Guo, Xiyi Huang, Shaomin Yang, Jialing Pan, Liwen Wang, Ming Chen, Fan Xie, Yunjing Li, Yongxing Du, Xinjie Chen, Qiugen Hu, Fusheng Ouyang","doi":"10.1002/mef2.100","DOIUrl":"https://doi.org/10.1002/mef2.100","url":null,"abstract":"<p>The detection of lymph node (LN) involvement is fundamental for staging colorectal cancer (CRC) and aids in clinical decision-making. Traditionally, determining LN status predominantly relies heavily on histological examination of LN specimens, which can occasionally lead to overtreatment. This study aims to develop a clinical prediction model using machine learning algorithms to assess the risk of mesenteric LN metastasis preoperatively, based on computed tomography images and clinicopathological data from CRC patients. Our findings demonstrate that the predictive model based on XGBoost algorithms exhibited the optimal performance, with area under the curve values consistently stable across training (0.836, 95% confidence interval [CI]: 0.750–0.902) and validation (0.831, 95% CI: 0.688–0.927) cohorts. The model was further elucidated using SHapley Additive Explanation values, which ranked predictors in the XGBoost model by their importance, providing insights into the model's decision-making process. Additionally, the force plot visualizes the contribution of each variable to the prediction for individual samples. The as-obtained model may have the potential to aid in clinical treatment planning, optimize the selection of surgical methods, and guide the decision-making process for adjuvant therapy before surgery.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhaoyong Liu, Chengbin Guo, Jing Guo, Shan Huang, Peng Du
Periodontal disease is a prevalent inflammatory condition affecting the tissues and bone surrounding the teeth, posing significant challenges to oral health. Current treatments often fall short due to incomplete removal of bacteria and plaque, irreversible damage to gums and bone, and their cost and time-consuming nature. Stem cell therapy offers a promising alternative that potentially addresses these limitations. This review delves into the biology, mechanisms, and applications of dental stem cells (DSCs) in alveolar bone and periodontal regeneration. We begin with an overview of various stem cell types and their characteristics, highlighting their role in tissue regeneration and the mechanisms involved. Subsequently, we examine preclinical and clinical studies that demonstrate the efficacy and safety of DSC therapy, showcasing their potential in restoring periodontal health. The discussion also extends to the critical challenges and future directions in the field, emphasizing the necessity for standardized protocols and rigorous research to fully integrate DSC-based therapies into routine clinical practice. This review underscores the transformative potential of DSCs in regenerative dentistry, aiming to provide a comprehensive understanding that can propel further advancements and ultimately improve patient outcomes in periodontal therapy.
{"title":"Research progress on application of dental stem cells in alveolar bone and periodontal regeneration","authors":"Zhaoyong Liu, Chengbin Guo, Jing Guo, Shan Huang, Peng Du","doi":"10.1002/mef2.98","DOIUrl":"https://doi.org/10.1002/mef2.98","url":null,"abstract":"<p>Periodontal disease is a prevalent inflammatory condition affecting the tissues and bone surrounding the teeth, posing significant challenges to oral health. Current treatments often fall short due to incomplete removal of bacteria and plaque, irreversible damage to gums and bone, and their cost and time-consuming nature. Stem cell therapy offers a promising alternative that potentially addresses these limitations. This review delves into the biology, mechanisms, and applications of dental stem cells (DSCs) in alveolar bone and periodontal regeneration. We begin with an overview of various stem cell types and their characteristics, highlighting their role in tissue regeneration and the mechanisms involved. Subsequently, we examine preclinical and clinical studies that demonstrate the efficacy and safety of DSC therapy, showcasing their potential in restoring periodontal health. The discussion also extends to the critical challenges and future directions in the field, emphasizing the necessity for standardized protocols and rigorous research to fully integrate DSC-based therapies into routine clinical practice. This review underscores the transformative potential of DSCs in regenerative dentistry, aiming to provide a comprehensive understanding that can propel further advancements and ultimately improve patient outcomes in periodontal therapy.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.98","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yiming Qin, Zihan Chen, Ye Peng, Ying Xiao, Tian Zhong, Xi Yu
Protein structure prediction (PSP) has been a prominent topic in bioinformatics and computational biology, aiming to predict protein function and structure from sequence data. The three-dimensional conformation of proteins is pivotal for their intricate biological roles. With the advancement of computational capabilities and the adoption of deep learning (DL) technologies (especially Transformer network architectures), the PSP field has ushered in a brand-new era of “neuralization.” Here, we focus on reviewing the evolution of PSP from traditional to modern deep learning-based approaches and the characteristics of various structural prediction methods. This emphasizes the advantages of deep learning-based hybrid prediction methods over traditional approaches. This study also provides a summary analysis of widely used bioinformatics databases and the latest structure prediction models. It discusses deep learning networks and algorithmic optimization for model training, validation, and evaluation. In addition, a summary discussion of the major advances in deep learning-based protein structure prediction is presented. The update of AlphaFold 3 further extends the boundaries of prediction models, especially in protein-small molecule structure prediction. This marks a key shift toward a holistic approach in biomolecular structure elucidation, aiming at solving almost all sequence-to-structure puzzles in various biological phenomena.
{"title":"Deep learning methods for protein structure prediction","authors":"Yiming Qin, Zihan Chen, Ye Peng, Ying Xiao, Tian Zhong, Xi Yu","doi":"10.1002/mef2.96","DOIUrl":"https://doi.org/10.1002/mef2.96","url":null,"abstract":"<p>Protein structure prediction (PSP) has been a prominent topic in bioinformatics and computational biology, aiming to predict protein function and structure from sequence data. The three-dimensional conformation of proteins is pivotal for their intricate biological roles. With the advancement of computational capabilities and the adoption of deep learning (DL) technologies (especially Transformer network architectures), the PSP field has ushered in a brand-new era of “neuralization.” Here, we focus on reviewing the evolution of PSP from traditional to modern deep learning-based approaches and the characteristics of various structural prediction methods. This emphasizes the advantages of deep learning-based hybrid prediction methods over traditional approaches. This study also provides a summary analysis of widely used bioinformatics databases and the latest structure prediction models. It discusses deep learning networks and algorithmic optimization for model training, validation, and evaluation. In addition, a summary discussion of the major advances in deep learning-based protein structure prediction is presented. The update of AlphaFold 3 further extends the boundaries of prediction models, especially in protein-small molecule structure prediction. This marks a key shift toward a holistic approach in biomolecular structure elucidation, aiming at solving almost all sequence-to-structure puzzles in various biological phenomena.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.96","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142316636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>The CAPability-01 trial, led by Feng Wang et al.,<span><sup>1</sup></span> was published in <i>Nature Medicine</i> on March 04, 2024. This study highlighted that a triplet regimen of the programmed cell death protein-1 (PD-1) monoclonal antibody sintilimab with the histone deacetylase inhibitor (HDACi) chidamide with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab significantly improved the progression-free survival (PFS) and response in microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC).</p><p>CAPability-01 trial is a randomized, open-label, multicenter, Phase 2 clinical trial, that evaluated the efficacy of a triplet therapy (sintilimab, chidamide, and bevacizumab) versus a doublet (sintilimab with chidamide) in patients with unresectable, chemotherapy-refractory, locally advanced or metastatic MSS/pMMR CRC. Forty-eight patients were enrolled and randomly assigned in a 1:1 ratio to receive the triplet or doublet treatment.</p><p>The study found that the triplet regimen outperformed the doublet regimen in most key endpoints. More than 50% of the patients presented with liver metastases or lung metastases at baseline. Treatment histories were diverse, with almost half of the patients, particularly in the doublet group, receiving third-line or later treatment. The triplet treatment group exhibited a significantly higher PFS rate and improved overall response rate (ORR) and disease control rate (DCR) compared to the doublet group, with 44% achieving partial response and 28% maintaining stable disease. Subgroup analysis revealed that patients with liver metastases benefited more from the triplet treatment, showing significantly notably better outcomes in PFS (7.3 months vs. 1.4 months, <i>p</i> = 0.001), ORR (50.0% vs. 8.3%), and DCR (71.4% vs. 8.3%) compared with those on the doublet regimen. In this study, the incidence rates of treatment-related side effects (TEAEs) occurred in 60.0% of patients in the triplet group and 30.4% in the doublet therapy. Grade 3 or higher adverse events included thrombocytopenia, reported in 16.0% of patients receiving triplet therapy compared to 8.7% in the doublet group, and neutropenia, which was reported at 28.0% for the triplet therapy and not at all for the doublet. The triplet regimen appeared promising for patients with MSS/pMMR unresectable advanced or metastatic CRC, providing longer progression-free survival and manageable toxicity.</p><p>Despite the advancements in chemotherapy and target therapy, the prognosis of most patients with unresectable locally advanced or metastatic CRC remains poor. Several studies are currently evaluating the effectiveness of immune checkpoint inhibitors (ICIs), antiangiogenesis therapy, and HDAC inhibitors in treating microsatellite instability-high/deficient mismatch repair phenotypes (MSI-H/dMMR) CRC (Table 1). ICIs, like PD-1 antibodies and CTLA-4 antibodies, have demonstrated impressive clinical benefit
{"title":"CAPability-01: Success of anti-PD-1, HDAC inhibitor, and anti-VEGF combination in colorectal cancer","authors":"Yujie Tan, Yunfang Yu","doi":"10.1002/mef2.97","DOIUrl":"https://doi.org/10.1002/mef2.97","url":null,"abstract":"<p>The CAPability-01 trial, led by Feng Wang et al.,<span><sup>1</sup></span> was published in <i>Nature Medicine</i> on March 04, 2024. This study highlighted that a triplet regimen of the programmed cell death protein-1 (PD-1) monoclonal antibody sintilimab with the histone deacetylase inhibitor (HDACi) chidamide with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab significantly improved the progression-free survival (PFS) and response in microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC).</p><p>CAPability-01 trial is a randomized, open-label, multicenter, Phase 2 clinical trial, that evaluated the efficacy of a triplet therapy (sintilimab, chidamide, and bevacizumab) versus a doublet (sintilimab with chidamide) in patients with unresectable, chemotherapy-refractory, locally advanced or metastatic MSS/pMMR CRC. Forty-eight patients were enrolled and randomly assigned in a 1:1 ratio to receive the triplet or doublet treatment.</p><p>The study found that the triplet regimen outperformed the doublet regimen in most key endpoints. More than 50% of the patients presented with liver metastases or lung metastases at baseline. Treatment histories were diverse, with almost half of the patients, particularly in the doublet group, receiving third-line or later treatment. The triplet treatment group exhibited a significantly higher PFS rate and improved overall response rate (ORR) and disease control rate (DCR) compared to the doublet group, with 44% achieving partial response and 28% maintaining stable disease. Subgroup analysis revealed that patients with liver metastases benefited more from the triplet treatment, showing significantly notably better outcomes in PFS (7.3 months vs. 1.4 months, <i>p</i> = 0.001), ORR (50.0% vs. 8.3%), and DCR (71.4% vs. 8.3%) compared with those on the doublet regimen. In this study, the incidence rates of treatment-related side effects (TEAEs) occurred in 60.0% of patients in the triplet group and 30.4% in the doublet therapy. Grade 3 or higher adverse events included thrombocytopenia, reported in 16.0% of patients receiving triplet therapy compared to 8.7% in the doublet group, and neutropenia, which was reported at 28.0% for the triplet therapy and not at all for the doublet. The triplet regimen appeared promising for patients with MSS/pMMR unresectable advanced or metastatic CRC, providing longer progression-free survival and manageable toxicity.</p><p>Despite the advancements in chemotherapy and target therapy, the prognosis of most patients with unresectable locally advanced or metastatic CRC remains poor. Several studies are currently evaluating the effectiveness of immune checkpoint inhibitors (ICIs), antiangiogenesis therapy, and HDAC inhibitors in treating microsatellite instability-high/deficient mismatch repair phenotypes (MSI-H/dMMR) CRC (Table 1). ICIs, like PD-1 antibodies and CTLA-4 antibodies, have demonstrated impressive clinical benefit","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.97","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}